One way to accomplish this is to set up a new and enforceable Covid-19 Vaccine Investment and Trade Agreement (CVITA)
(Not just investment facilitation. Subsidies scaling up input production capacity - shortages of lipids, bioreactor bags, syringes, etc are a problem...)
10/
CVITA can draw lessons from US subsidization and coordination of its entire domestic vaccine manufacturing supply chain under Operation Warp Speed. It was not easy to get even that supply chain to work together.
China actually bought more from the US in 2020 than in 2019, including of those "phase one" products.
China even bought relatively more from the US of those goods than it bought from the rest of the world... 2/
But both comparisons are irrelevant for the LEGAL agreement. (Read the text.)
Under the threat of continued tariff escalation, Trump convinced Beijing in December 2019 to commit to an additional $200bn on top of *2017* trade flows—not 2019.
More downside to US unilateralism. Even to protect national security.
European semiconductor and equipment makers accuse US of using export controls on Huawei and SMIC to shut them out of the Chinese market, while exempting US companies.
Multilateralizing export controls is hard. But the failure to do so could end up undermining the underlying rationale - the protection of national security - and punish American companies' commercial interests in the long run.